Diaceutics (LON:DXRX) Hits New 12-Month High – Here’s What Happened

Diaceutics PLC (LON:DXRX)’s stock price reached a new 52-week high during trading on Wednesday . The company traded as high as GBX 193 and last traded at GBX 185.86, with a volume of 1030922 shares. The stock had previously closed at GBX 186.

Wall Street Analyst Weigh In

Separately, Canaccord Genuity Group reissued a “buy” rating and issued a GBX 215 price objective on shares of Diaceutics in a report on Tuesday. Two equities research analysts have rated the stock with a Buy rating, According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus price target of GBX 215.

Diaceutics Trading Down 0.1%

The business’s 50 day simple moving average is GBX 145.97 and its two-hundred day simple moving average is GBX 150.95. The stock has a market cap of £157.72 million, a P/E ratio of 1,689.61 and a beta of 0.88. The company has a quick ratio of 9.92, a current ratio of 3.43 and a debt-to-equity ratio of 2.85.

Diaceutics (LON:DXRX) last announced its quarterly earnings results on Tuesday, September 22nd. The company reported GBX (3.27) EPS for the quarter. Diaceutics had a net margin of 0.25% and a return on equity of 0.25%. As a group, analysts expect that Diaceutics PLC will post 1.0107919 EPS for the current year.

Diaceutics Company Profile

At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome. We provide the world’s leading pharma and biotech companies with an end-to-end commercialisation solution for precision medicines through data analytics, scientific and advisory services enabled by our platform DXRX – The Diagnostics Network®.